Research on the cost-effectiveness of GLP-1 therapy depends on what a model measures and whose costs it uses. This study simulated kidney disease prevention for people with type 2 diabetes in German statutory insurance [1].
Projected benefits and costs
For men in the model starting at age 62.8, projected quality-adjusted life years were 10.28 with standard care, 10.48 with empagliflozin, 10.58 with semaglutide and 10.75 with tirzepatide. Each drug was modeled as an addition to standard care [1]. Projected microalbuminuria was 31.46% with standard care versus 25.39% with added tirzepatide [1].
For those same modeled men, the highest projected lifetime direct cost was about €155,993 with tirzepatide, versus about €84,329 for semaglutide. At the study's threshold of €100,000 per quality-adjusted life year, semaglutide had the highest net monetary benefit and tirzepatide had the lowest.
What changes the result
In a cost per patient reaching a target analysis, the threshold defines what is counted as a result. In this study, the researchers assigned a monetary value to each quality-adjusted year and subtracted expected costs.
The results depend on German costs, the input estimates for each drug and the chosen threshold. The researchers compared model projections, rather than outcomes from one head-to-head kidney trial.